Condition (MeSH)
Hemosiderosis
ClinicalTrials.gov lists 16 trials for Hemosiderosis or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 16 trials are tagged with Hemosiderosis itself; the rest are tagged with a narrower condition beneath it.
When did Hemosiderosis trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2007 | 2 |
| 2005 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemosiderosis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Observational | 7 |
How many Hemosiderosis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 11 |
| Terminated | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemosiderosis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| ApoPharma | 1 |
| Novartis | 1 |
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Deferasirox FCT | 5 |
| Deferoxamine mesylate only | 2 |
| Steroid Drug | 1 |
| Cohort | 1 |
| Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemosiderosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 16 | 2 |
| Abdominal pain | 7 | 1 |
| Sepsis | 6 | 2 |
| Vomiting | 6 | 2 |
| Anaemia | 5 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hemosiderosis? (29)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy on 1.5T T2*-Weighted Imaging. | Cerebrovascular diseases (Basel, Switzerland) | 2023 | Yes |
| Infratentorial superficial siderosis: Classification, diagnostic criteria, and rational investigation pathway. | Annals of neurology | 2017 | Yes |
| Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia. | Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance | 2017 | Yes |
| Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. | British journal of haematology | 2014 | Yes |
| The palatability and tolerability of deferasirox taken with different beverages or foods. | Pediatric blood & cancer | 2013 | Yes |
Showing 5 of 29 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.